Why it's included Included for its supportive role in metabolic function and its potential to help ease nausea, which can occur with GLP-1 therapies
The launch of this new innovative tool marks an important step forward in the mission and focus of our business, said Anna Mohl, CEO of Nestl Health Science
El efecto rebote de Ozempic, y en general de todos los agonistas GLP-1, aparece cuando una persona interrumpe el tratamiento de forma brusca
Clinical data from the SURMOUNT-1 trial published in the New England Journal of Medicine demonstrated dose-dependent weight loss: 16% average body weight reduction at 5mg, 21.4% at 10mg, and 22.5% at 15mg over 72 weeks
Aesthet Surg J
Experts note that long-term data on safety and effectiveness remain limited, particularly regarding bone health, fracture risk, and other adverse outcomes